Barclays
SNDX icon

Barclays’s Syndax Pharmaceuticals SNDX Stock Holding History

Barclays’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
+49,600
New +$1.03M ﹤0.01% 2744

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Barclays's SNDX Position: Q2 2026 in Review

Barclays reduced its Syndax Pharmaceuticals (SNDX) stake by 3.2% in Q2 2026, selling an estimated $33.9K and leaving 48,695 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2756.

Barclays first reported a position in SNDX in Q2 2016 and has held it in 41 quarters since. The position peaked at $24.5M in Q4 2022. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Barclays held 48,695 shares of Syndax Pharmaceuticals worth $1.06M as of Q2 2026.
  • Barclays sold 1,628 Syndax Pharmaceuticals shares in Q2 2026, an estimated $33.9K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2756 holding.
  • Barclays first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
  • Barclays's Syndax Pharmaceuticals position peaked at $24.5M in Q4 2022.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.